LEXARIA BIOSCIENCE CORP. Proceeds from Sale and Maturity of Marketable Securities
LEXARIA BIOSCIENCE CORP. (LEXX) reported Proceeds from Sale and Maturity of Marketable Securities of $0 for the 12-month period ending 2021-08-31, per its 10-K filed 2021-11-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2021-11-29
- LEXARIA BIOSCIENCE CORP. proceeds from sale and maturity of marketable securities for the quarter ending 2021-08-31 was $0.00.
- LEXARIA BIOSCIENCE CORP. proceeds from sale and maturity of marketable securities for the quarter ending 2020-08-31 was $0.00.
- LEXARIA BIOSCIENCE CORP. proceeds from sale and maturity of marketable securities for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- LEXARIA BIOSCIENCE CORP. proceeds from sale and maturity of marketable securities for fiscal 2020 was $6.80K.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|
| 2021-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-29 | $0.00 10-K · filed 2021-11-29 | |
| 2021-05-31 | $0.00 10-Q · filed 2021-07-15 | ||
| 2020-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-29 | $6.80K 10-K · filed 2021-11-29 | |
| 2020-05-31 | $6.80K 10-Q · filed 2021-07-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |